Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

World’s Largest Study on Sleep Apnea Suggests Apps Improve Patient Adherence

XTALKS VITALS NEWS

Sleep Apnea

This observational study followed patients using sleep apnea devices, which were remotely monitored by their physician, or by themselves.

Share this!

October 26, 2016 | by Sarah Hand, M.Sc.

According to the results of a 128,000-patient study conducted by ResMed, sleep apnea patients who use a self-management app in conjunction with positive airway pressure (PAP) are more likely to adhere to their therapy. ResMed is a global medical device company, focused on using cloud-based apps to help patients manage their chronic disease.

“This new study shows that online self-monitoring tools engage patients and significantly improve their compliance and adherence to treatment,” said ResMed Medical Director Dr. Adam Benjafield. “While our study focused on PAP users, we believe these results may be generalized more broadly in terms of the role online tools can have in improving medical treatment compliance overall.”

According to ResMed, poor patient adherence to treatment places an estimated $290 billion burden on the US healthcare system every year. Poor adherence increases the likelihood of disease progression, and these patients are more likely to be admitted to the hospital.



This observational study followed patients using sleep apnea devices, which were remotely monitored by their physician, or by themselves. ResMed’s myAir cognitive behavior-based app was used to monitor the patient’s adherence to the therapy.

Over 87 percent of PAP users were compliant when using myAir for self-monitoring, in conjunction with AirView for clinician remote monitoring. Patients who were only monitored using AirView showed 70 percent compliance to their therapy. Despite advances in continuous positive airway pressure (CPAP) therapy for sleep apnea patients, as few as 50 percent of people adhere to the therapy in the absence of digital monitoring.

“Half of all patients don't take their medications as prescribed, and we know that same statistic holds true for compliance with PAP therapy for sleep apnea,” said Benjafield. “The effects of poor treatment adherence are profound, not only for the number of people suffering due to poor medication adherence, but also in terms of emergency room visits, hospitalizations and their financial burden to the healthcare system.”

As a companion to AirView, myAir could help patients ensure they’re following the proper advice of their clinician on how to best manage their sleep apnea. ResMed will present further study data at this year’s American College of Chest Physicians (CHEST) annual meeting.


Keywords: Sleep Apnea, Patient Adherence, Medical Device


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.